Facing the
COVID-19 challenge


In these exceptional circumstances,
what we do matters more than ever

Since the pandemic began, Grifols has made its expertise in plasma available to health authorities, governments, regulatory agencies and society in general. At Grifols, we believe this current and extraordinary situation requires healthcare companies like ours to strive further to serve patients and society.

For over a century Grifols has been a healthcare company at the vanguard of blood- and plasma-therapy development, with the aim of enhancing people's health and well-being.

At the forefront of clinical trials to create treatments, as well as screening tests, to mitigate the global COVID-19 pandemic

In Grifols we believe in the therapeutic potential of human plasma and its components. During this unprecedented health crisis, plasma from patients who have recovered from COVID-19, called convalescent plasma, has been identified as a therapeutic option that can potentially help combat the disease.

This plasma from recovered COVID-19 donors contains antibodies which are specific against SARS-CoV-2, the virus that causes COVID-19. These antibodies are proteins called immunoglobulins, which help the body fight the infectious disease.

Convalescent plasma can be used:

  • For direct transfusion.
  • To develop a medicine, a hyperimmune globulin.

Anti-SARS-CoV-2 hyperimmune globulin

Grifols has been applying its broad knowledge and deep expertise in producing immunoglobulins to manufacture a specific anti-SARS-CoV-2 hyperimmune globulin for COVID-19. The clinical trial evaluating the safety, efficacy and tolerability of the
anti-SARS-CoV-2 hyperimmune globulin started in October. It's the first international multicenter clinical trial of an anti-SARS-CoV-2 hyperimmune and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals covering 18 countries.

Convalescent plasma for transfusion

In addition to the hyperimmune globulin, Grifols is also carrying out several clinical trials to evaluate the safety and efficacy of convalescent plasma for direct transfusion. On August 23, the FDA gave emergency-use authorization (EUA) for convalescent plasma to treat hospitalized COVID-19 patients.

Helping our donors provide their valuable plasma

Grifols is collecting plasma from recovered COVID-19 patients using its network of more than 300 donor centers in the U.S. and Germany, the largest global network of donation centers in the world. Our experienced technicians are specially trained and prepared to help our donors, whose generous and compassionate contributions enable us to develop potential treatments. Grifols is also collecting convalescent plasma in Spain through a collaboration with blood banks.

We're also proud to be part of a coalition of world-class medical and research institutions, blood centers, life-science companies, philanthropic organizations and COVID-19 survivor groups that has come together to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their plasma. Visit TheFightIsInUs.org.

COVID-19 Diagnostic and Screening Tests

Enabling the detection of the novel coronavirus SARS-CoV-2 through diagnostic and screening tests.


Read more


Supporting external research, such as GigaGen Inc.'s recombinant polyclonal antibodies therapy or the initiative led by the consortium including IrsiCaixa, Barcelona Supercomputing Center (BSC) and Food and Agriculture Science and Technology Institute (IRTA-CReSA) to discover vaccine prototypes and antibody therapeutics for SARS-CoV-2.

Community Support

Organizing food drives to aid communities and providing donations of personal protection equipment to the areas most impacted by the pandemic. In addition, technical and logistical support to hospitals for the storage, preparation and dispensing of medicines as well as the refurbishment and expansion of facilities to treat COVID-19 patients.